Short-course enzalutamide in recurrent prostate cancer slashes PSA, but PSMA-PET tumor volume misleads, raising overtreatment concerns.
Ravi Madan, MD
Ravi Madan, MD, is the acting deputy chief of the Genitourinary Malignancies Branch of the Center for Cancer Research, National Cancer Institute.
Articles by Ravi Madan, MD